Simple comparison of the stroke rate following SRS and RT is, however, confounded by the heterogenicity of treatment received and the background stroke risk of patients with uncontrolled growth hormone levels and the sequelae of acromegaly. This evidence concerns the gene GH1 and stroke disorder.